316. Carnitine cycle disorder Clinical trials / Disease details
Clinical trials : 4 / Drugs : 10 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00983788 (ClinicalTrials.gov) | October 2009 | 23/9/2009 | Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects | Evaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD Deficiency | Carnitine Palmitoyltransferase II Deficiency;Very Long Chain Acyl Coa Dehydrogenase Deficiency | Drug: Bezafibrate;Other: Placebo | Rigshospitalet, Denmark | Institut de Myologie, Pitié-Salpêtrière Hospital, France | Completed | 18 Years | 70 Years | Both | 12 | Phase 2 | Denmark |
| 2 | NCT00336167 (ClinicalTrials.gov) | June 2006 | 9/6/2006 | Bezafibrate Trial in CPT2 Deficiency | Clinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 Deficiency | Carnitine Palmitoyl Transferase 2 Deficiency | Drug: bezafibrate (drug) | Assistance Publique - Hôpitaux de Paris | Association Française contre les Myopathies (AFM), Paris;Institut National de la Santé Et de la Recherche Médicale, France | Recruiting | 18 Years | N/A | Both | 12 | Phase 3 | France |